Clinical trial
An Open-Label Evaluation of the Dose Proportionality of OROS Hydromorphone HCL…
NCT00398957 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00398957 |
|---|---|
| Title | An Open-Label Evaluation of the Dose Proportionality of OROS Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg |
| Official title | An Open Label Evaluation of the Dose Proportionality of Dilaudid SR (OROS Hydromorphone HCL) Tablets 8mg, 16mg, 32mg, and 64mg |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Analgesia |
| Intervention type | Drug |
| Interventions | OROS® Hydromorphone HCL, OROS® Dilaudid, Dilaudid SR (slow release), Naltrexone (an opioid antagonist). |
| Enrollment | 32 |
| Completion | Sep 1, 1998 |
| First posted | Nov 14, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: